Assessment of the efficacy of topical antiandrogen; spironolactone in patients with androgenetic alopecia by dermoscopy
DOI:
https://doi.org/10.66344/jpad.v32i3.1976Abstract
Background Androgenetic Alopecia (AGA) is a non-scarring alopecia characterized by progressive miniaturization of hair follicles with a distinctive distribution in genetically prone males & females. Topical Spironolactone is commonly used as off-label anti-androgen for managment of AGA.
Objective Assessing role of topical 1% spironolactone on hair thickness & count in patients with AGA using dermoscopy.
Methods 26 patients (16 males and 10 females) with ages ranging from 26 to 59 years with a mean±SD of 42.77±6.62 received topical 1% spironolactone solution to apply on the scalp once daily for at least six months. All patients had positive family history. Dermoscopy was performed on fixed areas on the scalp. Images were taken with a digital camera that was connected to the dermoscope just before starting treatment and after 6 months continuous treatment.
Results Significant increase in total terminal, terminal thick and total hair count in female patients along with a significant increase in total terminal, terminal thin, vellus and total hair count in male ones after treatment with topical 1% spironolactone were seen. However, thin and vellus hair in female and thick hair in male revealed no significant difference post spironolactone treatment.
Conclusion Spironolactone is an effective & harmless treatment in both females & males with AGA.
References
1. Rathnayake D, Sinclair R. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Dermatol Clin. 2010;8(3):611-8.
2. Gonzalez ME, Cantatore-Francis J, Orlow SJ. Androgenetic alopecia in the pediatric population: a retrospective review of 57 patients. Br J Dermatol. 2010;163:378-85.
3. Otberg N, Finner AM, Shapiro J. Androgenetic alopecia. Endocrinol Metab Clin North Am. 2007;36:379-98.
4. Birch MP, Lalla SC, Messenger AG. Female pattern hair loss. Clin Exp Dermatol. 2002;27:383-8.
5. Ludwig E.Classification of the types of androgenetic alopecia (common baldness) occurring in female sex. Br J Dermatol. 1977;97:247-54.
6. Messenger AG, Sinclair R. Follicular miniaturization in female pattern hair loss: clinicopathological correlations. Br J Dermatol. 2006;155:926-30.
7. Savin RC.A method for visually describing and quantitating hair loss in male pattern baldness. J Invest Dermatol.1992;98:604.
8. Tobin DJ, Gunin A, Magerl M, et al. Paus R. Plasticity and cytokinetic dynamics of the hair follicle mesenchyme: implications for hair growth control. J Invest Dermatol. 2003;120:895-904.
9. Yasmeen K, Carolyn G. Androgenetic alopecia: update on epidemiology, pathophysiology, and treatment. J Egyptian Women's Dermatologic Soc. 2013; 10(3):107-16.
10. Inui S, Itami S. Androgen actions on the human hair follicle: perspectives. Exp Dermatol. 2013;22:168-71.
11. Olsen EA, Hordinsky M, Roberts JL, et al. Female pattern hair loss. J Am Acad Dermatol. 2002;47:795.
12. Kaufman KD. Androgens and alopecia. Mol Cell Endocrinol. 2002;198:89-95.
13. Schweikert HU, Wilson JD. Regulation of human hair growth by steroid hormones I. Testerone metabolism in isolated hairs. J Clin Endocrinol Metab. 1974;38:811-9.
14. Heilmann S, Kiefer AK, Fricker N, et al. Androgenetic alopecia: identification of four genetic risk loci and evidence for the contribution of WNT signaling to its etiology. J Invest Dermatol. 2013;133:1489-96.
15. Andl T, Reddy ST, Gaddapara T, et al. Signals are required for the initiation of hair follicle development. Dev Cell. 2002;2:643-53.
16. Shimizu H, Morgan BA. Wnt signaling through the beta-catenin pathway is sufficient to maintain, but not restore, anagen-phase characteristics of dermal papilla cells. J Invest Dermatol. 2004;122:239-45.
17. Garza LA, Liu Y, Yang Z, et al. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med. 2012;4:126ra34.
18. Smith S, Fagien S, Whitcup SM, et al. Eyelash growth in subjects treated with bimatoprost: a multicenter, randomized, double- masked, vehicle-controlled, parallel-group study. J Am Acad Dermatol. 2012;66:801-6.
19. Blume-Peytavi U, Lonnfors S, Hillmann K, et al. A randomized doubleblind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol. 2012;66:794-800.
20. Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150:186-94.
21. Mella JM, Perret MC, Manzotti M, et al. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol. 2010;146:1141-50.
22. Sinclair R, Wewerinke M, Jolly D. Treatment of female pattern hair loss with oral antiandrogens. Br J Deramtol. 2005;152:466-73.
23. Paradisi R, Porcu E, Fabbri R, et al. Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss. Ann Pharmacother. 2011;45:469-75.
24. Garza LA, Yang CC, Zhao T, et al. Bald scalp in men with androgenetic alopecia retains hair follicle stem cells but lacks CD200-rich and CD34- positive hair follicle progenitor cells. J Clin Invest. 2011;121:613-22.
25. Desai S, Mahmoud BH, Bhatia AC,. Paradoxical hypertrichosis after laser therapy: a review. Dermatol Surg. 2010; 36:291-298.
26. Kang JS, Zheng Z, Choi MJ,.The effect of CD34+ cell-containing autologous platelet-rich plasma injection on pattern hair loss: a preliminary study. J Eur Acad Dermatol Venereol. 2014;28(1):72-9
27. Eppley BL, Pietrzak WS, Blanton M.Platelet-rich plasma: a review of biology and applications in plastic surgery. Plast Reconstr Surg. 2006;118:147-59.
28. Rey FO, ValterioC, Locatelli L. et al. Lack of endocrine systemic side effects after topical application of spironolactone in man. J Endocrinol Invest. 1988;11:273-8.
29. Ross EK, Vincenzi C, Tosti A. Videodermoscopy in the evaluation of hair and scalp disorders. J Am Acad Dermatol. 2006;55:799-806.
30. Tosti A, Torres F. Dermoscopy in the diagnosis of hair and scalp disorders. Actas Dermosifiliogr.2009;100(Suppl 1):114-9.
31. Ramos PM, Miot HA. Female pattern hair loss: a clinical and pathophysiological review. An Bras Dermatol. 2015;90(4):529‐ 43.
32. Rathnayake D, Sinclair R. Male androgenetic alopecia .Expert Opin. Pharmacother. 2010;11(8):1295-1304.
33. Imperato McGinley J. % alpha reductase 2 deficiency and complete androgen insensitivity: lesions from nature. Adv Exp Med Biol. 2002;511:121-34.
34. Kaufman KD, Olsen EA, Whiting D. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39:578-89.
35. Yip LD, Sinclair RD. Antiandrogen therapy for androgenetic alopecia Leona, Review. Expert Rev Dermatol. 2006;1(2):261-9.
36. Shaw JC. Antiandrogen therapy in dermatology. Int J Dermatol. 1996;35(11): 770-6.
37. Sato, K, Matsumoto D, Iizuka F. et al. Anti-androgenic Therapy Using Oral Spironolactone for Acne Vulgaris in Asians. Aesth Plast Surg. 2006;30:689-94.
38. Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol. 2005;152:466-73.
39. Dinh Q Q , Sinclair R. Female pattern hair loss: Current treatment concepts. Clin Interven Aging. 2007;2(2):189-99.
40. Fabbrocini G, Cantelli M, Masarà A, et al. Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. Int J Women's Dermatol.2018;4:203-11.
41. Yousef AE, Abdelshafy AS, Almabrouk M. Topical Finasteride vs Topical Spironolactone in the Treatment of Androgenetic Alopecia. Med J Cairo Univ.2020;88(3):1017-22.
42. Dill-Muller D, Zaun H. Topical treatment of androgenetic alopecia with spironolactone. J Eur Acad Dermatol Venereol. 1997;9(Suppl 1):31.
43. Abdel‐Raouf H, Aly UF, Medhat W, et al. A Novel Topical Combination of Minoxidil and Spironolactone for Androgenetic Alopecia: Clinical, Histopathological and Physico‐Chemical Study. Dermatol Ther. 2020;12-15.
44. Vargas-Mora P, Morgado-Carrasco D. Spironolactone in Dermatology: Uses in acne, hidradenitis suppurativa female pattern baldness, and hirsutism. Actas Dermosifiliogr. 2020;111:639-49.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Sherief Mahdy Hussein, Ahmed M Soliman, Sameh Hosam Abd El-Alim, Ahmed Alaa Kassem, Hanaa Emam, Hany Shehata, Ahmad Abdelmaksood Rabie, Hanan Farouk Aly, Yasmin Bakr El Zawahry
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
